Prognostic testing in Brazilian patients with uveal melanoma using 15-gene expression profile and preferentially expressed antigen in melanoma

1. Instituto Suel Abujamra de Oftalmologia, São Paulo, SP, Brazil
2. University of Miami Miller School of Medicine, Bascom Palmer Eye Institute, Miami, FL, USA
3. Department of Ophthalmology and Vision Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
4. Department of Ophthalmology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
5. Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA
6. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

Zelia M. Correa
E-mail: [email protected]

Disclosure of potential conflicts of interest: J.W.H. is the inventor of intellectual property related to prognostic testing in uveal melanoma. He is a paid consultant for Castle Biosciences, the licensee of this intellectual property, and receives royalties from its commercialization. Z.M.C. has served as a consultant for Castle Biosciences, Inc. All remaining authors declare no competing financial interests. Castle Biosciences, Inc. had no role in the study design; in the collection,